Elucid raises $55m to advance cardiovascular diagnostic portfolio

Elucid intends to apply the proceeds towards accelerating the commercial expansion of its clinical platform that includes its Plaque-IQ diagnostic. Elucid intends to apply the proceeds towards accelerating the commercial expansion of its clinical platform that includes its Plaque-IQ diagnostic. The latest financing brings Elucid’s total funds raised to date to around $185m. Credit: Anusorn Nakdee/Shutterstock.com Elucid has raised $55m to further develop its artificial intelligence (AI)-based cardiovascular imaging platform and support preparations for the anticipated US Food and Drug Administration (FDA) clearance of its fractional flow reserve (FFR)-CT software. Bringing its total funding to date to around $185m, the…

Source: Medical Device Network